Summary of BeOne Medicines FY Conference Call Company Overview - **Company**: BeOne Medicines (NasdaqGS:BGNE) - **Event**: 46th Annual Healthcare Conference from TD Cowen - **Date**: March 02, 2026 Key Points Financial Guidance and Revenue - **Revenue Guidance**: BeOne Medicines provided a revenue guidance of **$6.2 billion to $6.4 billion** for FY 2026, reflecting a **$1 billion year-over-year growth** [6][9] - **Q4 Performance**: The company reported a strong exit from Q4, with significant growth across all geographies, particularly in the US and China markets [7][13] - **Market Dynamics**: The guidance considers competitive dynamics, including stable net pricing in the US market [8][12] Competitive Landscape - **Competitors**: The company acknowledged competition from AVEO and Jaypirca, noting that AVEO was not approved, which positively impacts BeOne's market position [11] - **Market Leadership**: BRUKINSA was established as the **number 1 BTK globally** in 2025, with a **14% sequential growth** in Q4 compared to Q3, while competitors grew by only **4%** [13][14] Regional Growth - **US and China**: Strong growth was noted in both the US and China, with BRUKINSA leading in these markets [13] - **Europe and Rest of World**: The European business nearly tripled in 2024 and grew over **70%** in 2025, while the rest of the world markets grew by more than **100%** [14] Research and Development (R&D) - **Pipeline Expansion**: The company is expanding its pipeline with multiple programs in various phases, including BCL-2 and BTK degrader [20][24] - **Investment Strategy**: BeOne Medicines is committed to both growth and margin expansion, having generated over **$940 million in free cash** in 2025 [24] - **Partnership Considerations**: The company is evaluating potential partnerships for certain assets but has the capability to develop most of its programs independently [26] Clinical Trials and Drug Development - **CDK4 Program**: The CDK4 program is set to start trials, with a focus on operational excellence and rapid enrollment [35][38] - **GPC3 and CEA-ADC**: The GPC3 ADC has shown promising results, with FDA granting Fast Track designation, and plans for registrational studies are underway [51][55] - **B7H4 ADC**: The B7H4 ADC is in development, with initial studies planned for breast or gynecologic cancers [57][62] Market Potential and Strategy - **BCL-2 Class**: The BCL-2 class, particularly with sonrotoclax, is expected to unlock significant market potential due to its usability and safety profile compared to existing treatments like Venetoclax [73][74] - **Multiple Myeloma Opportunity**: Plans to initiate a phase 3 study in multiple myeloma are in place, targeting patients with specific genetic translocations [76] Future Outlook - **Regulatory Engagement**: The company is actively engaging with regulatory authorities to expedite the development of its promising candidates [51] - **Data Disclosures**: BeOne Medicines plans to share data from various programs at major medical congresses throughout the year, indicating a robust pipeline and ongoing commitment to transparency [43][55] Additional Insights - **Operational Efficiency**: The company has demonstrated a high success rate in moving molecules from early to late-stage development, with a focus on stopping underperforming programs [31] - **Innovative Approaches**: BeOne Medicines is leveraging its unique clinical development model to enhance efficiency and reduce costs in drug development [23] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting BeOne Medicines' strong market position, growth potential, and commitment to innovation in oncology.

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5]. Core Insights - The company reported total revenue of $5.3 billion for 2025, a year-on-year increase of 40%, and achieved a GAAP net profit of $287 million, marking a return to profitability [2]. - The sales of the core product, Zebutinib, continued to grow rapidly, with Q4 2025 sales reaching $1.15 billion, a 39% increase year-on-year [3]. - The company provided guidance for 2026, projecting total revenue between $6.2 billion and $6.4 billion, with GAAP operating expenses of $4.7 billion to $4.9 billion and a gross margin in the high 80% range [3]. Financial Performance - The company’s revenue is expected to grow from $5.34 billion in 2025 to $6.43 billion in 2026, reflecting a growth rate of 20.27% [10]. - The net profit forecast for 2026 is adjusted to $685 million, with a significant growth rate of 138.6% compared to 2025 [10]. - The diluted earnings per share (EPS) is projected to be $0.44 in 2026, up from $0.19 in 2025 [10]. Research and Development Pipeline - The company is advancing its R&D pipeline, with several key milestones expected in 2026, including interim analysis for Zebutinib in MCL and potential approvals for other products [4]. - The company anticipates data releases for various clinical trials in the first half of 2026, which could serve as catalysts for future growth [4].

Core Viewpoint - The innovative drug sector in the A-share market has shown significant recovery in 2025, with many companies reporting revenue and profit growth, driven by new drug launches and business development (BD) authorization income [1][8]. Group 1: Performance Highlights - Among the 39 innovative drug concept stocks that disclosed their 2025 performance reports, 29 companies achieved year-on-year revenue growth, and 25 companies reported profit growth or reduced losses [1][7]. - Notable companies like BeiGene (百济神州) and Rongchang Bio (荣昌生物) have turned losses into profits, indicating an expanding profitability landscape in the innovative drug sector [6][1]. - BeiGene reported a revenue of 38.205 billion yuan in 2025, a 40.4% increase year-on-year, and a net profit of approximately 1.422 billion yuan, marking its first annual profit [4][3]. Group 2: Growth Drivers - The primary drivers for revenue growth among these companies include the rapid market release of new drugs and significant income from BD authorizations [8][10]. - For instance, Haichuang Pharmaceutical (海创药业) saw its revenue surge by over 55 times, primarily due to the launch of its first Class 1 new drug, which was approved for sale in May 2025 [8][9]. - Companies like Zhixiang Jintai (智翔金泰) also benefited from expanding sales of their commercialized products and substantial licensing income from BD agreements [8][10]. Group 3: Financial Performance - Zhixiang Jintai achieved a revenue of 231 million yuan in 2025, a 666.65% increase year-on-year, while its net loss decreased from 799.27 million yuan to 536.22 million yuan [9]. - Sanofi (三生国健) reported the highest net profit among the 39 stocks, with a revenue of 4.199 billion yuan, a 251.81% increase, and a net profit of 2.939 billion yuan, a 317.09% increase [9][10]. Group 4: Challenges and Market Dynamics - Despite the positive trends, 9 companies reported revenue declines, with Yifang Bio (益方生物) experiencing the largest drop at 77.89%, leading to an increased net loss [11][12]. - The commercial path for innovative drugs remains challenging, as evidenced by companies like Baili Tianheng (百利天恒) and Shenzhou Cell (神州细胞), which also reported declines in revenue and net profit [12].

Core Viewpoint - The article discusses the challenges and potential catalysts for Hengrui Medicine, highlighting the need for stable revenue contributions from BD transactions and the growth of innovative drug sales to restore market confidence [5][52]. Group 1: Current Market Situation - Hengrui Medicine has not seen significant market performance recently, contrasting with peers like Rongchang Biopharmaceutical and Geely Pharmaceutical, which have experienced double-digit stock price increases [4]. - Despite a warming capital market, Hengrui has faced a rare "eleven consecutive declines" in stock price, leading to negative annual fluctuations [4][5]. Group 2: BD Transactions and Performance - BD transactions have become a crucial driver for Hengrui's performance since 2024, but concerns about the sustainability of this model have emerged due to delayed revenue recognition [9][17]. - In 2023, Hengrui received €160 million (approximately RMB 1.2 billion) from BD transactions, and in 2024, it expects to confirm $100 million (approximately RMB 700 million) from Kailera Therapeutics [9][10]. - The company completed five BD transactions before September 2025, securing $783 million and €15 million in upfront payments, along with potential milestone payments totaling $15.8 billion, indicating a significant increase in transaction frequency and scale [13]. Group 3: Innovation and Product Pipeline - Hengrui's innovative drug sales and licensing revenue reached RMB 95.61 billion in the first half of 2025, accounting for about 60% of total revenue, indicating a shift towards "innovation-driven" growth [24]. - The company has received approvals for 17 innovative drugs from 2021 to 2024, creating a diversified product matrix that reduces reliance on single blockbuster products [23]. - Hengrui's innovative drugs, such as Haiqubopai, have shown strong market potential, with sales expected to exceed RMB 1 billion in 2024 [23]. Group 4: Challenges Ahead - Hengrui faces challenges, including a reliance on a "fast-follow" research model, which raises concerns about competition from similar products in the market [30]. - The company lacks a globally recognized blockbuster product, with its most successful products primarily concentrated in the domestic market [32][33]. - Hengrui's internationalization efforts are still in the early stages, with no innovative products approved for sale in overseas markets yet [34]. Group 5: Future Catalysts - Key signals to watch for include the maturation of the BD business model, sustained growth in innovative drug revenue (targeting a compound annual growth rate of over 25%), and breakthroughs in the research pipeline [39][41][42]. - The upcoming FDA review of Hengrui's "dual-Ai" therapy for liver cancer is a critical milestone that could significantly impact the company's international strategy and market perception [49][50].

Core Viewpoint - BeiGene has demonstrated strong execution in Q4 2025, achieving significant product revenue growth and solid cash flow, with its lead product, Brukinsa (Zebutinib), becoming the top BTK inhibitor globally [1][4][17]. Financial Performance - Q4 2025 product revenue reached $1.5 billion, a 33% year-over-year increase, with Brukinsa global revenue of $1.1 billion, up 38% [3][17]. - For the full year 2025, Brukinsa generated $3.9 billion in global revenue, reflecting a 49% increase [3][17]. - Gross margin improved to 87%, with operating profit of $447 million and GAAP net profit of $287 million for Q4 2025 [3][19]. - The company expects total revenue for 2026 to be between $6.2 billion and $6.4 billion, with GAAP operating expenses projected at $4.7 billion to $4.9 billion [3][21]. Product Development and Pipeline - In 2025, BeiGene made significant progress in R&D, with the approval of ZS in China for relapsed/refractory MCL and CLL, and ongoing regulatory reviews in the US and EU [2][8]. - The company is advancing multiple clinical trials, including three Phase 3 trials for BTK degraders and a combination therapy for HER2-positive gastric cancer [2][8][14]. - BeiGene aims to establish Brukinsa as a foundational treatment in CLL, with plans to expand its use in fixed-duration treatment regimens [10][11]. Market Position and Strategy - Brukinsa has established itself as the leading BTK inhibitor, with a market share of approximately 50% in the CLL treatment space [7][27]. - The company is targeting three ambitious goals for CLL innovation, focusing on improving patient outcomes and treatment options [6][10]. - BeiGene is also expanding its pipeline beyond CLL, with ongoing research in various hematologic malignancies and solid tumors [11][12][13]. Future Catalysts - Key upcoming milestones include the initiation of a global Phase 3 study comparing ZS with another oral fixed-duration treatment in newly diagnosed CLL patients [16][21]. - The company plans to submit a marketing application for ZS in combination with chemotherapy for HER2-positive gastric cancer in mid-2026 [16][21]. - BeiGene is also set to report on several concept validation studies in immunology throughout 2026 [16].

Investment Rating - The report maintains a "Buy" rating for the company, 百济神州 (6160 HK) [2][11]. Core Insights - The company demonstrated strong product sales in Q4 2025, with revenue reaching USD 1.476 billion, a year-on-year increase of 32%. The sales of the drug, Zejula, amounted to USD 1.1 billion, with a significant market share in the US [6]. - The company is increasing its R&D investments in 2026, focusing on pipeline development and prioritizing management, which is expected to yield multiple catalysts [2][6]. - The revenue guidance for 2026 is set between RMB 62-64 billion, with a projected non-GAAP net profit of RMB 14-15 billion [6]. Financial Performance - The company’s revenue for 2026 is forecasted at RMB 6,317 million, a decrease of 3% from previous estimates. The gross profit is expected to be RMB 5,564 million, down by 1% [5]. - The gross profit margin is projected to be 88.0%, an increase of 0.9 percentage points compared to previous estimates [5]. - The GAAP net profit for 2026 is estimated at RMB 750 million, reflecting a 15% decrease from prior forecasts [5]. Stock Performance - The stock price closed at HKD 194.40, with a target price adjusted to HKD 229.20, indicating a potential upside of 17.9% [1][11]. - The stock has shown a year-to-date change of 8.42% [4]. Pipeline Development - The company is focusing on four core strategic areas for pipeline development: chronic lymphocytic leukemia (CLL), other hematological malignancies, solid tumors, and inflammation/immune diseases [6]. - Key upcoming milestones include the potential approval of Sotigalimab in the US and Europe, and the initiation of several clinical trials for new therapies [6].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 229.20, indicating a potential upside of 17.9% from the current price of HKD 194.40 [1][11]. Core Insights - The company has shown strong sales performance in Q4 2025, particularly with the drug Zebutinib, which achieved sales of USD 1.1 billion, reflecting a year-on-year increase of 38% [6]. - The company is focusing on enhancing its research and development efforts in 2026, with a revenue guidance of USD 6.2 to 6.4 billion and a non-GAAP net profit forecast of USD 1.4 to 1.5 billion [6]. - The company is strategically prioritizing its pipeline development in four key areas: chronic lymphocytic leukemia (CLL), other hematological malignancies, solid tumors, and inflammation/immunology [6]. Financial Performance - For 2026, the company is projected to generate revenue of RMB 6,317 million, with a gross profit of RMB 5,564 million, resulting in a gross margin of 88.0% [5][12]. - The GAAP net profit for 2026 is estimated at RMB 750 million, with a net profit margin of 11.9% [5][12]. - The company’s stock price has shown a year-to-date increase of 8.42% [4]. Market Position - Zebutinib holds approximately 50% market share among BTK inhibitors and about 25% among all treatment options for 1L CLL patients in the U.S. market [6]. - The company is expected to maintain its leading position in the slow-growing lymphoma market, with new drug approvals anticipated in 2026 [6]. Valuation - The DCF valuation model estimates the equity value of the company at approximately USD 45.27 billion, translating to a per-share value of HKD 229.20 [7].

Core Insights - After turning profitable, BeiGene (688235.SH, 06160.HK, NASDAQ: BGNE) has demonstrated significant growth momentum, with 2025 revenue reaching 38.205 billion yuan, a year-on-year increase of 40.4%, and a net profit of 1.422 billion yuan, recovering from a loss of 4.978 billion yuan in the previous year [2][3] Financial Performance - In 2025, BeiGene's product revenue was 37.77 billion yuan, up 39.9% year-on-year [2] - The company reported a net profit of 1.422 billion yuan for 2025, compared to a loss of 4.978 billion yuan in the same period last year [2] - The company had a cumulative net loss of approximately 59.1 billion yuan from 2017 to 2024, averaging over 20 million yuan in daily losses [2] Revenue Drivers - The growth in product revenue for 2025 was primarily driven by the sales of Baiyueze (Zebutinib), licensed products from Amgen, and Baizean (Tislelizumab) [3][4] - Baiyueze's global sales reached 28.067 billion yuan in 2025, marking a 48.8% increase, solidifying its position as a global leader in the BTK inhibitor market [3] - Sales in the U.S. totaled 20.206 billion yuan, up 45.5%, while Europe and China saw increases of 66.4% and 33.1%, respectively [3] R&D Investment - BeiGene has consistently invested over 10 billion yuan in R&D for four consecutive years, with cumulative R&D expenses reaching 49.264 billion yuan, accounting for approximately 60% of total revenue during this period [6][7] - R&D expenses for 2025's first three quarters were 11.159 billion yuan, a 9.77% increase year-on-year, representing about 40% of the revenue for that period [6] Product Development - Baiyueze is noted for having the broadest range of approved indications among BTK inhibitors globally, with over 45 clinical trials conducted across more than 30 countries [7] - Baizean is positioned as a cornerstone product in BeiGene's solid tumor portfolio, with ongoing clinical development in over 33 countries and more than 15,800 participants enrolled [8] - The company plans to submit new indication applications for Baizean in the U.S. and China in the first half of 2026 [8] Future Outlook - BeiGene anticipates strong financial performance in Q4 2025 and throughout the year, highlighting its competitive advantages in clinical development and a differentiated R&D pipeline [9]

Core Viewpoint - BeiGene has achieved a significant milestone by reporting a net profit of 1.422 billion yuan for the fiscal year 2025, marking its first annual profit and indicating a new phase of sustainable profitability for the innovative pharmaceutical company [1]. Financial Performance - The total revenue for 2025 reached 38.205 billion yuan, representing a substantial year-on-year increase of 40.4% [1]. - The product revenue amounted to 37.770 billion yuan, showing a growth of 39.9% compared to the previous year [2]. Product Performance - The growth in product revenue is primarily driven by the sales of the BTK inhibitor Brukinsa (Zebutinib) and the sales of licensed products from Amgen and Tislelizumab [2]. - Brukinsa's global sales reached 28.067 billion yuan in 2025, with notable growth across regions: 20.206 billion yuan in the U.S. (up 45.5%), 4.265 billion yuan in Europe (up 66.4%), and 2.472 billion yuan in China (up 33.1%) [2]. Research and Development Pipeline - BeiGene's R&D pipeline is expanding, with several key products nearing commercialization, including the BCL2 inhibitor, which has received priority review from the FDA and is expected to receive regulatory decisions in 2026 [4]. - The company is also advancing multiple new drugs targeting high-incidence tumors such as breast cancer and lung cancer, with several trials expected to commence in 2026 [5]. Market Position and Future Outlook - As a benchmark for Chinese innovative drugs on a global scale, BeiGene's 2025 performance highlights its development breakthroughs and the competitive edge of Chinese original innovative drugs in the global market [6]. - The company is poised to further solidify its global market position with the commercialization of new drugs and the continuous expansion of existing product indications [6].

Group 1: Industry Investment Rating - The investment rating for the overseas social services industry is positive, with a focus on the record-high visitor numbers during the Macau Spring Festival [6]. Group 2: Core Insights - The total number of inbound visitors to Macau during the Spring Festival reached 1.554 million, with an average daily visitor count of 173,000, marking a year-on-year increase of 5.5% [6][1]. - Among the inbound visitors, mainland tourists averaged 134,000 per day, reflecting a 7% year-on-year growth, while international visitors averaged nearly 7,900 per day, up by 8% [6][1]. - The hotel occupancy rate during the Spring Festival was 95.6%, with the highest rate of 99.2% recorded on the fourth day of the festival [6][1]. Group 3: Summary by Relevant Sections Overseas Pharmaceuticals - The report highlights significant developments in the pharmaceutical sector, including the announcement of clinical trial results for B7-H3 ADC by Yingensheng and the completion of Phase II trials for UBT251 by Lianbang Pharmaceutical [3][10]. - In 2025, BeiGene reported revenues of $5.343 billion, a 40% increase year-on-year, while adjusted net profits reached $917 million, marking a return to profitability [9][21]. - The report also notes that the average weight loss in the UBT251 trial was as high as 19.7% after 24 weeks, compared to a 2.0% loss in the placebo group [11][10]. Overseas Education - The vocational education sector is experiencing an upswing, with promising enrollment data, particularly for China Oriental Education [5][17]. - The education index saw a decline of 4.9% in the recent week, underperforming the Hang Seng National Enterprises Index by 2.1 percentage points [15]. - The report recommends focusing on China Oriental Education, which is expected to see accelerated enrollment growth due to its strategic adjustments in response to market demands [17][15].